Osteoporosis Clinical Pipeline | 30+ Companies, Including mAbxience, Alvotech, GlycoNex, and Surrozen, Driving the Next Breakthroughs

The Osteoporosis market is evolving with cutting-edge research and new therapeutic advancements.

DelveInsight's 'Osteoporosis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline Osteoporosis therapies in various stages of clinical development. Major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Osteoporosis pipeline domain.

For Osteoporosis emerging drugs, the Osteoporosis pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

Key Takeaways from the Osteoporosis Pipeline Report
• DelveInsight's Osteoporosis Pipeline analysis depicts a robust space with 30+ active players working to develop 35+ pipeline drugs for Osteoporosis treatment.
• The leading Osteoporosis companies include mAbxience, Alvotech, Transcenta Holding, Suzhou Suncadia Biopharmaceuticals, GlycoNex, Cellatoz Therapeutics, Enzo Biochem, Surrozen, and others are evaluating their lead assets to improve the Osteoporosis treatment landscape.
• Key Osteoporosis pipeline therapies in various stages of development include EB613, AVT03, RT-102, TST002, Denosumab biosimilar, and others.
• In November 2024, the FDA accepted the biologics license application for HLX14, a denosumab (PROLIA/XGEVA) biosimilar, from Organon and Shanghai Henlius Biotech, approved for treating postmenopausal women at high fracture risk.
• In April 2024, Entera Bio published Phase II trial data for EB613 for postmenopausal women with low bone mineral density (BMD) or osteoporosis in the Journal of Bone and Mineral Research (JBMR).
• In March 2024, the FDA communicated that it would issue a ruling on the use of treatment-related changes in BMD as a surrogate endpoint for fractures in future osteoporosis drug trials within 10 months.

Request a sample and discover the recent breakthroughs happening in the Osteoporosis pipeline landscape @ https://www.delveinsight.com/report-store/osteoporosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Osteoporosis Overview
Osteoporosis is a bone disease characterized by a reduction in bone mineral density and bone mass, or structural deterioration of bone tissue, leading to weakened bones and an increased risk of fractures. Often referred to as a "silent disease," osteoporosis typically does not cause noticeable symptoms until a fracture occurs. Osteoporosis symptoms may include severe back pain, loss of height, and spinal deformities like kyphosis (hunched posture) due to vertebral fractures. The condition is a major cause of fractures, particularly in postmenopausal women and older men, with the most commonly affected bones being the hip, spine, and wrist. Osteoporosis stages of disease progress silently, often remaining undetected until a bone break results from minor falls or even routine activities like bending, lifting, or coughing. While the disease can affect individuals of all races and genders, it is most common in non-Hispanic white and Asian women and, to a lesser extent, in non-Hispanic white men.

Since osteoporosis does not present clear physical signs in its early stages, diagnosis typically requires a DEXA (dual-energy X-ray absorptiometry) scan to measure bone density. The U.S. Preventive Services Task Force recommends osteoporosis screening for women over 65 years old and younger women with significant risk factors. Risk factors for osteoporosis include aging, hormonal changes, poor nutrition, and lifestyle factors such as inactivity and smoking. Osteoporosis medications aim to slow bone loss, improve bone density, and reduce the risk of fractures. Treatment often involves bisphosphonates, hormone therapy, and newer biologic agents targeting bone resorption and formation. For those with secondary osteoporosis, managing the underlying condition is crucial to preventing further bone deterioration and improving overall bone health.

Find out more about Osteoporosis medication @ https://www.delveinsight.com/report-store/osteoporosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Osteoporosis Treatment Analysis: Drug Profile
AVT03: Alvotech
AVT03 is a human monoclonal antibody and a biosimilar candidate to Prolia and Xgeva (denosumab). Denosumab targets and binds with high affinity and specificity to the RANK ligand membrane protein, preventing the RANK ligand/RANK interaction from occurring, resulting in reduced osteoclast numbers and function, thereby decreasing bone resorption and cancer-induced bone destruction. AVT03 is an investigational product and has not received regulatory approval in any country. Currently, the drug is in Phase III stage of its development for the treatment of osteoporosis.

TST002: Transcenta Holding
TST002 (Blosozumab) is a humanized anti-sclerostin monoclonal antibody as a drug candidate for osteoporosis and other bone loss diseases. It has a dual effect possessing both anabolic and anti-resorptive effects, which stimulates bone formation and inhibits bone absorption, resulting in fast increase in bone mineral density and bone strength. Blocking sclerostin activity in human treated with anti-sclerostin antibody or with naturally occurring genetic deletion has been shown to be an effective approach in increasing bone mineral density (BMD) and reducing bone fracture. Currently, the drug is in Phase II stage of its clinical trial for the treatment of osteoporosis.

Key Osteoporosis Therapies and Companies
• EB613: Entera Bio
• AVT03: Alvotech
• RT-102: Rani Therapeutics
• TST002: Transcenta Holding
• Denosumab biosimilar: GlycoNex

Learn more about the novel and emerging Osteoporosis pipeline therapies @ https://www.delveinsight.com/report-store/osteoporosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Osteoporosis Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

By Molecule Type
• Oligonucleotide
• Peptide
• Small molecule

Scope of the Osteoporosis Pipeline Report
• Coverage: Global
• Key Osteoporosis Companies: mAbxience, Alvotech, Transcenta Holding, Suzhou Suncadia Biopharmaceuticals, GlycoNex, Cellatoz Therapeutics, Enzo Biochem, Surrozen, and others.
• Key Osteoporosis Pipeline Therapies: EB613, AVT03, RT-102, TST002, Denosumab biosimilar, and others.

Dive deep into rich insights for drugs used for Osteoporosis treatment; visit @ https://www.delveinsight.com/report-store/osteoporosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Osteoporosis Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Osteoporosis Pipeline Therapeutics
6. Osteoporosis Pipeline: Late-Stage Products (Phase III)
7. Osteoporosis Pipeline: Late-Stage Products (Phase III)
8. Osteoporosis Pipeline: Mid-Stage Products (Phase II)
9. Osteoporosis Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.